Melbourne (Australia) | 26 February 2025
Telix today announces new Director appointments as part of a Board succession planning and renewal process.
- H Kevin McCann AO will retire as Non-Executive Director (NED) and Board Chairman on 21 May 2025, following Telix’s Annual General Meeting. Mr. McCann is Telix’s inaugural public company Chairman and has served since the Company’s listing on the ASX in November 2017. For close to eight years, Mr. McCann’s tireless service and strategic direction have been instrumental to Telix’s growth and success.
- Tiffany Olson will be appointed Board Chair following Mr. McCann’s retirement[1]. Ms. Olson was appointed as a NED in March 2022 and has deep experience in commercialization and corporate strategy in oncology, including in the radiopharmaceuticals sector. Ms. Olson is based in Indianapolis, Indiana, U.S.
- Marie McDonald will join the Board as NED, effective 3 March 2025 and, on appointment, will immediately succeed Mr. McCann as Chair of the People Committee[2]. Ms. McDonald, based in Melbourne, Australia, is an experienced Director of several ASX-listed life science companies including CSL and Nanosonics. She brings significant experience in financial markets, mergers and acquisitions, regulatory policy, remuneration, risk management and compliance. Ms. McDonald practised for 30 years as a commercial lawyer for law firm Ashurst Australia and was previously a long-serving member of the Australia Takeovers Panel.
The Board changes will support the Company’s growth trajectory, expanding global footprint and recent Nasdaq dual-listing. The Board continues to assess the skills and experience needed for strong stewardship and governance and intends to make an additional U.S.-based NED appointment in the near future.
Mr. McCann said, “It has been a great privilege to serve on the Telix Board and contribute to the Company’s success to date. I am grateful to Dr. Behrenbruch and my other fellow Directors for their invaluable support and dedication to Telix’s purpose. I am delighted that the Board has appointed Tiffany to succeed me in the role of Board Chair. She will bring radiopharmaceuticals expertise, energy and strategic insights to the role. Additionally, the appointment of high-caliber Director, Marie McDonald, enhances the diversity of experience within the Board.”
Ms. Olson said, “It is an honor to be succeeding Kevin as the next Chair of Telix. This is a dynamic company with a compelling combination of talent, pipeline and commercial track record, and has an exciting future. I look forward to continuing to work with my fellow Directors and the executive team as we deliver outcomes to patients and shareholders.”
Telix Group CEO and Managing Director, Dr. Christian Behrenbruch added, “We are immensely thankful for Kevin’s outstanding service to Telix as our inaugural Chairman. He has consistently stood for a high standard of corporate governance, a patient-centric company culture and a strong focus on shareholder value creation. Kevin has also been a personal mentor and supporter during a period of extremely rapid growth, for which I am personally grateful. I am very welcoming of Tiffany and Marie’s leadership and what it means for the future trajectory of Telix.”
Read the full ASX release here
[1] Effective, 21 May 2025, immediately following Telix’s Annual General Meeting.
[2] The Board will dissolve the People, Culture, Nomination and Remuneration Committee and establish a new People Committee and Nomination Committee, effective 3 March 2025. Once effective, Committee Charters will be available on Telix’s website.